Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT05995873 |
| Other study ID # |
R44DA050358 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
January 22, 2024 |
| Est. completion date |
August 30, 2024 |
Study information
| Verified date |
August 2023 |
| Source |
MindLight, LLC |
| Contact |
Fredric Schiffer, MD |
| Phone |
781-405-8800 |
| Email |
fred.schiffermd[@]gmail.com |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
Investigators will test, for safety and efficacy, a novel treatment for opiate addiction that
applies a 4-minute treatment of intense near infra-red light to stimulate a side of the brain
that the investigators determine to be healthier, more mature, and less traumatized.
Investigators will compare among actively using participants an active and a sham treatment
given either once or twice weekly for 25-weeks at 2 sites. Investigators hope this will lead
to a significant weapon in the battle against the opioid epidemic as well as lead to
psychological and physiological insights into possible relations among trauma, cerebral
laterality, and addiction.
Description:
Approach. Investigators have had a and productive Pre-submission meeting with the FDA on
April 21, 2022, and are following their guidance in our approach. The goal of this Phase II
study is to test further the efficacy and safety of a new and innovative, patented
application of transcranial photobiomodulation for the treatment of opioid use disorder
(defined by DSM-5 criteria) with the possibility of achieving FDA clearance. The Opioid
Addiction Therapy System is a photobiomodulation device platform intended to be used alone or
as an aid to psychotherapy and medical-assisted treatments to treat opioid use disorder. It
is intended to be used by trained psychotherapists in clinical environments on patients with
opioid use disorder.
Specific Aim1:
1. Following FDA's preliminary guidance, Investigators aim first to assess whether active
Rx with UtPBM administered to the more positive hemisphere helps participants taper and
abstain from use of opioids as indicated by an increase in the percent of weekly visits
in which there was no self-reported use of opioids on TimeLine Follow Back and urine
screens for opioids were negative. This will be assessed from weeks 10 through 26, to
give participants sufficient time to taper off opioids. An additional primary outcome
will be the reduction in frequency of use (days per week) as assessed using timeline
feedback from baseline to week 26. Secondary outcome measures will include the
following: retention in treatment, opioid craving, withdrawal symptoms, clinical global
impression ratings of severity and improvement, quality of life metrics and Treatment
Success, as at least 80% opioid abstinence during weeks 10-26. An assessment will also
be made of adverse events during the treatment period.
Milestones: a. Investigators predict based on our Phase I findings that active treatment
will increase weekly abstinence rates by 20% or more over sham treatment (e.g., 30% vs
10% weekly opioid-negative visits). Investigators expect each of the secondary outcomes
to be significantly better in the active group with a p value of less than 0.05.
2. Investigators wish to see if actively treated participants age more slowly over the
26-week course of the study than those who receive the sham treatments. Investigators
will measure this by using epigenetic techniques. Investigators will use
state-of-the-art epigenetic measures of Intrinsic Epigenetic Age Acceleration to assess
subtype differences in DNA m. Investigators feel this is superior focusing on candidate
genes. Peripheral lymphocytes are the most appropriate cell type for assessing Intrinsic
Epigenetic Age Acceleration.
Sequence of Visits. Interested individuals will call to receive information and will complete
a brief screen for age and key exclusion criteria. Those who appear eligible will be invited
to interview. Visit 1 will consist of full study informed consent, structured interviews to
assess inclusion and exclusion criteria, TimeLine Followback to assess current degree of
substance use, urine drug screen and computerized assessment of hemispheric emotional
valence. Those who meet entrance criteria and agree to participate will be randomized into
active or sham groups. Treatment sessions will start with visit 1 and will occur twice weekly
for 6 weeks, then weekly until week 25 with one untreated follow-up session on week 26.
Within Session Protocol. Participants will give verbal reconsent to be in the study at each
study session. Immediately before each UtPBM active and sham treatment, the primary and the
secondary outcome measures will be recorded.
The active treatment will consist of applying PBM in the form of a super-luminous LED with an
output of 250 mW/cm2 at a frequency of 810 nM with a width of 40 nM when applied the skin for
a fluence of 60J/cm2. The treatment will consist of the exposure to the light for 4 minutes
at one of 2 sites on the forehead that correspond to the 10-20 electroencephalogram sites,
F3, and F4. Whether Investigators will treat at F3 or F4 will be determined by the tests of
HEV. Investigators will treat the side that is determined to have a more positive HEV. Based
on a penetration of 3.7% of the light to the dura, Investigators will be applying 2.1 Joules/
cm2 to the treated area of the brain. Our level of light exposure is well below the ANSI
standard of 0.32 W/cm2. The fluence of our device is 40 times less than the device that was
used in the study of 1410 stroke patients without any observed side-effects and was found in
a study of the rat brain exposed to light to cause no observable behavioral or cellular
alterations. The device has been determined by the FDA to be of no significant risk as
described in the attached FDA letter of September 8, 2022.
The sham treatment will be identical to the active treatment except that the LED will be
covered with aluminum foil to prevent near-infrared light from reaching the brain. The
treating clinician, who will not be blinded, will apply the either the active or the sham
treatment to the participant in a manner that does not allow either the recording clinician
or the patient to have any way to detect whether a given treatment is active or sham. When
asked in prior studies, neither the patients nor recorders were able to detect whether the
application was active or sham at the time of treatment.
Although Investigators believe that the procedures in this study are not expected to cause
adverse effects, during all procedures the researcher in attendance will closely observe the
subject for any adverse effects. All NIH and WCG IRB patient safety and monitoring procedures
will be followed. For any adverse events Investigators will use the NIH Adverse Events Form.
All serious adverse events will be report to the IRB, NIH and FDA and posted to
clinicaltrials.gov.
Subjects will not wear protective eyewear. The researcher administering the tPBM will be
careful to not shine the LED into the subjects' eyes. LEDs do not pose the level of danger to
the eyes that lasers present because the LED light is not coherent; still a person's staring
into a super-luminous LED for 4-minutes could potentially cause damage the eye, but a second
or two of looking at the LED will not cause harm. Photobiomodulation is currently used to
treat some retinal diseases.
Any subject who for any reason wishes to leave the study at any time before its conclusion,
of course, will be free to do so. If any unexpected, unacceptable adverse events are
observed, Investigators will discontinue the entire study until Investigators have fully
consulted with the IRB.
Each session will include use assessment of frequency and extent of opioid and other
substances, urine analysis with temperature check for drug use, pregnancy testing of female
participants, assessment of hemispheric emotional valence, symptom ratings and active or sham
UtPBM. Following treatment, participants who revealed drug use, or had a positive urine
assay, will be provided with instructions on how to safely taper opioid use (e.g., 10-20%
reduction per week if using daily, discontinuation if using less frequently). Participants
who have reduced intake from baseline will also be cautioned at each visit that there is an
increased risk for overdose if they abruptly return to a previously used higher dose as it
can take as little as a week to lose tolerance.
Investigators have extensive experience with our device and method and in clinical practice
and in a study, Investigators intentionally activated the negative hemisphere, and this can
cause the patient to feel his usual anxiety and symptoms but has never created a danger. All
treating personnel are well trained in our techniques. Investigators will not blame a failure
to reach our milestones on treatment of the wrong side; Investigators are testing our method
of determining the side of the greater HEV and treating it.
Outcome Measures: Primary Measure of efficacy will be percent abstinence from opioid use,
defined as the percent of each participant's weekly visits that are negative for opioid use
both on the use report and by urine analysis from weeks 10-26. If a participant misses a
visit, Investigators will attempt to contact them by phone for a use rating and to have them
provide a urine sample at a test center. Otherwise, all missed samples or ratings will be
defined as non-negative. In addition, Investigators will also assess whether there was a
significant difference between active and sham treatment in the frequency (days per week) of
use based on the use report, which Investigators have found in our studies to reveal a
greater degree of use than once or twice weekly urine tests, and which provides more
granularity than designating each week (or test) as positive or negative. This is the
approach that Investigators used to analyze opioid use from the phase I study and makes sense
as the proposed protocol does not include a detoxification stage.
Secondary Measures include the following standard outcome measures: retention in treatment,
opioid craving, withdrawal symptoms, clinical global impression ratings of severity and
improvement, and Treatment Success, as at least 80% opioid abstinence during weeks 10-26.
Secondary outcomes have been used in one or more of the RCTs designed to test the efficacy of
buprenorphine for opioid use disorder. Investigators will also include visual analog scale
ratings of quality of life and quality of relationships and the Hamilton Depression Rating
Scale and the Hamilton Anxiety Rating Scale.
Opioid craving will be assessed using the Opioid Craving Visual Analog Scale (0-100 mm).
Withdrawal symptoms will be assessed using the Clinical Opioid Withdrawal Scale.
Investigators will also use the Subjective Opiate Withdraw Scale and the Columbia Suicide
Severity Scale. Retention will be assessed as the number of sessions attended as determined
by their discontinuation or removal. Participants will be removed from the study if they
engage in a dangerous or sexually inappropriate manner with staff or have a positive
pregnancy test. Investigators will conduct analyses of both discontinuation, which will
include all participants who fail to complete the full trial, and a specific analysis of the
voluntary drop-out rate that would include participants who exit the study, are lost to
follow up, receive medication assisted treatment or other somatic modalities, but would
exclude legitimate unavoidable reasons for discontinuation such as pregnancy, parole
violation or verifiable illness or injury unrelated to current opioid use disorder that would
preclude participation.
Investigators will measure Intrinsic epigenetic age acceleration using the whole methylome
chip. For these analyses, Investigators will use the EWAS of that provides an epigenetic
measure of low-grade chronic inflammation from an additive weighted score of 58 replicated
CpG sites in European and African-Ancestry samples. Intrinsic epigenetic age acceleration
will be assessed from the Epic Methylome array. This parameter typically correlates highly
with chronological age, however, emerging evidence from our lab and others point to an
acceleration of epigenetic aging in response to cumulative lifetime stress, childhood
maltreatment, and post-traumatic stress disorder. All saliva samples will be stored and
processed at McLean Hospital which has specimen and data security in place.
